Giuseppe Carrà1,2, Francesco Bartoli1, Marc Galanter3, Cristina Crocamo1. 1. a Department of Medicine and Surgery , University of Milano Bicocca , Monza , Italy. 2. b Division of Psychiatry , University College London , London , UK. 3. c Department of Psychiatry , NYU School of Medicine , New York , NY , USA.
Abstract
OBJECTIVES: Despite growing concerns for non-medical use of prescription pain relievers (NMUPPRs), little is known about the role of comorbid, untreated depressive disorders. METHODS: We examined past year rates of NMUPPRs and major depressive episode (MDE), using data between 2008 and 2014 from the National Survey on Drug Use and Health for both youths (12-17 years) and adults (18 or older). Prevalence estimates with 95% confidence intervals were computed. Stratified analyses and generalized linear models were run to examine the association between NMUPPRs and MDE, controlling for treatments received for mental health and/or substance misuse. In order to explore whether MDE effect might change by treatment received, a model with an interaction term including MDE and treatment was fit. RESULTS: Among respondents, about 9% (youths) and 7% (adults) reported past year MDE and about 6% (youths), and 4% (adults) NMUPPRs. About 1.2% (youths) and 0.7% (adults) reported both MDE and NMUPPRs. Those with past year MDE were more likely to report NMUPPRs (RR, 95%CI: 2.60, 2.42-2.80, and 2.64, 2.47-2.82, for youths and adults). Considering the any treatment/MDE interaction on NMUPPRs, MDE risk ratio for subjects who received some treatment (youths: adjusted risk ratio (ARR) = 1.15; adults: ARR = 1.25) was about 70-80% as compared with their untreated counterpart (youths: ARR = 1.57; adults: ARR = 1.54). The likelihood of reporting NMUPPRs amongst respondents who did not receive any treatment was higher for those with past year MDE (main effect: youths ARR = 1.57, p < 0.001; adults ARR = 1.54, p < 0.001). CONCLUSION: Unrecognized and untreated depressive disorders should be considered for prevention, treatment, and policy implications in order to tackle NMUPPRs epidemic.
OBJECTIVES: Despite growing concerns for non-medical use of prescription pain relievers (NMUPPRs), little is known about the role of comorbid, untreated depressive disorders. METHODS: We examined past year rates of NMUPPRs and major depressive episode (MDE), using data between 2008 and 2014 from the National Survey on Drug Use and Health for both youths (12-17 years) and adults (18 or older). Prevalence estimates with 95% confidence intervals were computed. Stratified analyses and generalized linear models were run to examine the association between NMUPPRs and MDE, controlling for treatments received for mental health and/or substance misuse. In order to explore whether MDE effect might change by treatment received, a model with an interaction term including MDE and treatment was fit. RESULTS: Among respondents, about 9% (youths) and 7% (adults) reported past year MDE and about 6% (youths), and 4% (adults) NMUPPRs. About 1.2% (youths) and 0.7% (adults) reported both MDE and NMUPPRs. Those with past year MDE were more likely to report NMUPPRs (RR, 95%CI: 2.60, 2.42-2.80, and 2.64, 2.47-2.82, for youths and adults). Considering the any treatment/MDE interaction on NMUPPRs, MDE risk ratio for subjects who received some treatment (youths: adjusted risk ratio (ARR) = 1.15; adults: ARR = 1.25) was about 70-80% as compared with their untreated counterpart (youths: ARR = 1.57; adults: ARR = 1.54). The likelihood of reporting NMUPPRs amongst respondents who did not receive any treatment was higher for those with past year MDE (main effect: youths ARR = 1.57, p < 0.001; adults ARR = 1.54, p < 0.001). CONCLUSION: Unrecognized and untreated depressive disorders should be considered for prevention, treatment, and policy implications in order to tackle NMUPPRs epidemic.
Entities:
Keywords:
Non-prescription drugs; depression; epidemiologic factors; health surveys; treatment
Authors: Timothy E Wilens; Diana W Woodward; Je Deuk Ko; Amy F Berger; Colin Burke; Amy M Yule Journal: J Child Adolesc Psychopharmacol Date: 2022-05-04 Impact factor: 3.031
Authors: Chongliang Luo; Kun Chen; Riddhi Doshi; Nathaniel Rickles; Yong Chen; Harold Schwartz; Robert H Aseltine Journal: PLoS One Date: 2022-06-30 Impact factor: 3.752
Authors: Maria Francesca Moro; Gemma Calamandrei; Ranieri Poli; Valentina Di Mattei; Alessandra Perra; Peter Konstantin Kurotschka; Alexandra Restrepo; Ferdinando Romano; Giuseppe La Torre; Emanuele Preti; Franco Mascayano; Angelo Picardi; Flavia Chiarotti; Venerando Rapisarda; Antonio Urban; Ruben Alvarado; Ezra Susser; Mauro Giovanni Carta Journal: Front Psychiatry Date: 2022-06-02 Impact factor: 5.435